More U.S. Investors Join Arbitration Against South Korea Over Coupang Dispute 
ByteDance Advances AI Chip Development With Samsung Manufacturing Talks 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
CBA Shares Surge After Record Half-Year Profit as Rate Outlook Improves 
Ancora Holdings Builds $200M Stake in Warner Bros Discovery, Targets Netflix Asset Sale Plan 
Xiaomi EV Deliveries Surpass 600,000 Units as SU7 and YU7 Drive Strong Growth 
Vale Reports $3.8 Billion Q4 Net Loss Amid Nickel Asset Impairment and Samarco Provisions 
Air New Zealand Cabin Crew Strike Set for February 12–13 Amid Failed Talks 
Russia Moves to Fully Block WhatsApp as Kremlin Pushes State-Backed MAX App 
FTC Questions Apple News Over Alleged Bias Against Conservative Media 
Michael Kors Marks 45 Years at New York Fashion Week with Fall/Winter Collection Showcase 
Westpac (ASX: WBC) Q1 Profit Rises 6% as Lending Growth and Treasury Income Strengthen Earnings 
U.S. Commerce Department Reaches $252 Million Settlement With Applied Materials Over China Exports 
SMIC Shares Slide Despite Strong AI-Driven Earnings as Margin Pressure Looms 
U.S. Judge Allows Jeffrey Epstein Sex Trafficking Lawsuit Against Bank of America to Proceed 
BILLERICA, Mass., April 12, 2018 -- ConforMIS, Inc. (NASDAQ:CFMS) announced today that it will host a conference call on Wednesday, May 2, 2018, at 4:30 p.m. Eastern Time to discuss its financial results for the first quarter 2018. To participate in the conference call, please call 877-809-6331 (or 615-247-0224 for international) and use conference ID number 1695267.
The conference call will be hosted by Mark Augusti, President and Chief Executive Officer, and Paul Weiner, Chief Financial Officer. The company will issue a news release announcing its first quarter 2018 financial results on Wednesday, May 2, 2018, prior to the conference call.
A live webcast of the conference call will also be available in the investor relations section of the company’s website at ir.conformis.com. The online archive of the webcast will be available on the company’s website for 30 days.
About ConforMIS, Inc.
Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient's unique anatomy. Conformis offers a broad line of customized knee implants and pre-sterilized, single-use instruments delivered in a single package to the hospital. In clinical studies, Conformis iTotal CR demonstrated superior clinical outcomes, including better function and greater patient satisfaction, compared to traditional, off-the-shelf implants. Conformis owns or exclusively in-licenses approximately 420 issued patents and pending patent applications that cover customized implants and patient-specific instrumentation for all major joints.
For more information, visit www.conformis.com. To receive future releases in e-mail alerts, sign up at http://ir.conformis.com/.
Contact
Investor Contact:
Oksana Bradley
[email protected]
(781) 374-5598
